Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.31: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 10.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical with two products: Amtagvi (lifileucel), the first approved TIL cell therapy for advanced melanoma, and Proleukin (aldesleukin). Products are sold to US hospitals and clinics, with Amtagvi approved in the US and... Read more
Sell if holding. Engine safety override at $3.31: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 10.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole source vendors / limited manufacturers for TIL cell therapy manufacturing10-K Item 1A: 'we rely or may rely on treatment sites, limited manufacturers, sole source vendors, or a limited number of vendors, which could impair our ability to manufacture and supply our products'
Material Events(8-K, last 90d)
- 2026-03-20Item 5.02LOWDirector Wendy Yarno announced retirement from the Board and will not stand for re-election at the Annual Meeting anticipated June 2026. Departure not due to disagreement. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -148.4%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.31: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 10.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $3.09. Score 5.1/10, moderate confidence.
Take-profit target: $7.83 (+135.8% upside). Prior stop was $3.09. Stop-loss: $3.09.
Concentration risk — Supplier: sole source vendors / limited manufacturers for TIL cell therapy manufacturing; Quality below floor (2.8 < 4.0).
Iovance Biotherapeutics, Inc. trades at a P/E of N/A (forward -11.9). TrendMatrix value score: 8.0/10. Verdict: Sell.
17 analysts cover IOVA with a consensus score of 3.9/5. Average price target: $9.
What does Iovance Biotherapeutics, Inc. do?Iovance Biotherapeutics is a commercial-stage biopharmaceutical with two products: Amtagvi (lifileucel), the first...
Iovance Biotherapeutics is a commercial-stage biopharmaceutical with two products: Amtagvi (lifileucel), the first approved TIL cell therapy for advanced melanoma, and Proleukin (aldesleukin). Products are sold to US hospitals and clinics, with Amtagvi approved in the US and Canada.